Aggressive Lymphomas
From the Journals
Entospletinib falls short in relapsed/refractory DLBCL
The oral, selective inhibitor of spleen tyrosine kinase had a high rate of adverse events and treatment interruption in the phase 2 study.
Conference Coverage
Updated ThroLy system predicts need for thromboprophylaxis
DUBROVNIK, CROATIA – The revised ThroLy scoring system offers a lymphoma-specific system to predict thromboembolic events.
Conference Coverage
MCL treatment choices depend partly on age
CHICAGO – There are important treatment differences in patients aged 65 and younger versus those over 65.
News
Phase 1 NHL, ALL trials placed on clinical hold
Update: On October 12, 2018, Affimed N.V. received a notification from the U.S. Food and Drug Administration (FDA) saying the agency concurred...
News
Variant not associated with CLL, AIHA, or ITP in certain patients
DUBROVNIK, CROATIA—New research suggests there is no association between the PTPN22 R620W polymorphism and chronic lymphocytic leukemia (CLL) or...
News
System may better predict thrombosis in lymphoma
DUBROVNIK, CROATIA—An updated scoring system can more accurately identify lymphoma patients who may require thromboprophylaxis, according to...
News
Weighing the costs of CAR T-cell therapy
The cost-effectiveness of tisagenlecleucel (Kymriah) depends on long-term clinical outcomes, which are presently unknown, according to...
News
CAR T therapy being explored in Hodgkin lymphoma
New York—Although the data set is small and not yet mature, chimeric antigen receptor (CAR) T-cell therapy appears to be a promising approach for...
From the Journals
AITL responds to 5-azacytidine in small series
The small study showed high response and no significant safety concerns.
News
Duvelisib bests ofatumumab as monotherapy for treatment of CLL/SLL
Final analysis of the phase 3 DUO trial has shown monotherapy with oral duvelisib results in a statistically significant improvement in...
News
5-year remission rates with combo prove durable in MCL
Long-term results of a phase 2 clinical trial of the lenalidomide and rituximab combination as first-line therapy for mantle cell lymphoma (MCL)...